For VC and portfolio teams
See what the next pharma commitment depends on.
A positive meeting is different from an authorized pilot. Use intelligence-analysis methods to examine the assumptions behind a portfolio company’s opportunity.
Free case analyses and new-report announcements by email.
What supports the opportunity in the pipeline?
A company reports that its pharma sponsor is enthusiastic. That is useful information, but it leaves other questions open. Who can fund the pilot? Are source permissions clear? What evidence would justify the next customer commitment?
A signal
Sponsor interest
A person supports the idea.
A different commitment
Pilot authorization
Named owners approve a bounded test on agreed terms.
A later decision
What follows the pilot
The findings inform whether to proceed, revise, investigate further or stop.
Progress becomes easier to assess when the claim, the supporting evidence and the unknowns stay separate.
This is a way to examine partnership progress, not a valuation model. The current report’s focus is U.S. pharmaceutical commercial operations.
Make the reasoning visible.
Work through a question, the available evidence and what to do next.
Structured analytic techniques, in use
Key Assumptions Check
Which conditions is the commercial plan relying on?
The assumptions being tested
The company may assume its sponsor controls funding, the proposed sources can be used and the buyer wants to change the workflow. Ask which premises have been checked with the people responsible.
What the evidence establishes
A supportive sponsor has been identified.
What still needs confirmation
Spending authority, permissions and workflow ownership still need confirmation.
Assessment
Interest is established; authorization is not
How the decision changes
Make the next portfolio discussion specific: which premise needs investigation, and who can confirm it?
Quality of Information Check
What does “ready for a pilot” actually establish?
How to check the claim
Distinguish the company’s interpretation from a documented customer decision. Check the source, date and meaning of the evidence before using it as a commercial milestone.
What the evidence supports
A positive meeting supports interest.
Evidence still needed
A named approval, permitted evaluation scope and funding decision would establish a different state.
Assessment
The meeting establishes interest, not permission to start
How the decision changes
Record the actual customer decision and the remaining conditions. Avoid turning enthusiasm into an assumed commitment.
Indicators and Signposts
What observable event should change the assessment?
What to define
Name events that would justify revising the view of the opportunity.
What to look for next
The next review can look for a specific approval or condition, rather than another general update on the relationship.
Examples of useful signposts
A confirmed funding owner, a permitted source set or an agreed evaluation question can each change what the company should do next.
Assessment
The next review has a specific customer milestone
How the decision changes
Agree the next evidence to seek, its owner and when the opportunity should be reassessed.
These examples adapt structured analytic techniques described by the U.S. Government (2009).
Before the next investment
46%
What would justify continuing?
In 451 Research’s cross-industry survey, respondents estimated that their organizations abandoned an average of 46% of AI proofs of concept before production (Johnston, 2025).
The question was answered by 878 respondents whose organizations had AI or machine learning in production or proof of concept. Fieldwork ran from October 21 to November 25, 2024, in North America and Europe. This is a cross-industry finding, rather than a pharma-specific rate; it does not explain why an individual test stopped. For a portfolio team, the useful question is what the next test must establish before the customer commits again.
From the current issue
Deal Formation
From Interest to a Pilot Decision
Written for sponsors and AI providers, Report 01 follows a commercial partnership from initial interest through the pilot decision. Its examples focus on U.S. pharmaceutical commercial operations.
48-page PDF. Eight structured analytic techniques. $99 for one named reader.
The continuing series
Make the next opportunity review more specific.
Subscribe to Deal Design Intelligence for practical cases, analysis and new-report announcements. Examine the customer assumptions behind a proposed AI partnership and the evidence for its next commitment.
New analysis as it is published. Full reports are sold separately.
Strategic areas are optional. Leave them blank for the current enterprise AI partnership series, or select only the areas you want. Broader areas are proposed future coverage.
The sign-up form is loading.
Read how we handle information.